MCET (MultiCell Technologies) Total Assets: $0.30 Mil (As of Aug. 2015)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is MultiCell Technologies Total Assets?

MultiCell Technologies MCET -90.00% Total Assets is $0.30 Mil as of Aug. 2015.

MultiCell Technologies's Total Assets for the quarter that ended in Aug. 2015 was $0.30 Mil.

Total Assets is connected with ROA %. MultiCell Technologies's annualized ROA % for the quarter that ended in Aug. 2015 was -177.41%. Total Assets is also linked to Revenue through Asset Turnover. MultiCell Technologies's Asset Turnover for the quarter that ended in Aug. 2015 was 0.54.

MultiCell Technologies  (OTCPK:MCET) Total Assets Explanation

Total Assets is connected with ROA %.

MultiCell Technologies's annualized ROA % for the quarter that ended in Aug. 2015 is

ROA %=Net Income (Q: Aug. 2015 )/( (Total Assets (Q: May. 2015 )+Total Assets (Q: Aug. 2015 ))/ count )
=-0.636/( (0.421+0.296)/ 2 )
=-0.636/0.3585
=-177.41 %

Note: The Net Income data used here is four times the quarterly (Aug. 2015) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

MultiCell Technologies's Asset Turnover for the quarter that ended in Aug. 2015 is

Asset Turnover
=Revenue (Q: Aug. 2015 )/( (Total Assets (Q: May. 2015 )+Total Assets (Q: Aug. 2015 ))/ count )
=0.195/( (0.421+0.296)/ 2 )
=0.195/0.3585
=0.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

MultiCell Technologies Total Assets Related Terms

MultiCell Technologies Total Assets Historical Data

* Premium members only.

The historical data trend for MultiCell Technologies's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MultiCell Technologies Total Assets Chart

MultiCell Technologies Annual Data
Trend Nov05 Nov06 Nov07 Nov08 Nov09 Nov10 Nov11 Nov12 Nov13 Nov14
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.68 0.72 0.21 0.18 0.13

MultiCell Technologies Quarterly Data
Nov10 Feb11 May11 Aug11 Nov11 Feb12 May12 Aug12 Nov12 Feb13 May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.13 0.07 0.42 0.30

MultiCell Technologies Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

MultiCell Technologies's Total Assets for the fiscal year that ended in Nov. 2014 is calculated as

Total Assets=Total Equity (A: Nov. 2014 )+Total Liabilities (A: Nov. 2014 )
=-1.517+1.643
=0.13

MultiCell Technologies's Total Assets for the quarter that ended in Aug. 2015 is calculated as

Total Assets=Total Equity (Q: Aug. 2015 )+Total Liabilities (Q: Aug. 2015 )
=-1.621+1.917
=0.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $0.30 Mil mean?
MultiCell Technologies (MCET) has a Total Assets of $0.30 Mil as of Aug. 2015. The total amount of assets as recorded on a company's balance sheet. View historical data on MultiCell Technologies and its competitors.
Is MultiCell Technologies' Total Assets too high?
MultiCell Technologies' current Total Assets is $0.30 Mil.
How does MultiCell Technologies' Total Assets compare to ERGO and OPLI?
MultiCell Technologies' Total Assets of $0.30 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on MultiCell Technologies and its competitors. MultiCell Technologies's current Total Assets is $0.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MultiCell Technologies stock overvalued right now?
MultiCell Technologies (MCET) has a current Total Assets of $0.30 Mil. The current Total Assets is $0.30 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For MultiCell Technologies (MCET), the current Total Assets is $0.30 Mil as of Aug. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MultiCell Technologies Business Description

Address 4144 North Central Expressway, Suite 600, Dallas, TX, USA, 75204
MultiCell Technologies Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and others. Its therapeutic development platform includes several patented techniques used to isolate, characterize, and differentiate stem cells from the human liver or control the immune response at transcriptional and translational levels through dsRNA-sensing molecules, such as Toll-like receptor, RIG-I-like receptor, and MDA-5 signaling. The company's medical device development platform is based on the design of a next-generation bioabsorbable stent, the Ideal BioStent, for interventional cardiology and peripheral vessel applications. All the operations are functioned within United States.